Filing Flows › Black Diamond Therapeutics (BDTX) › Q1 2025
Black Diamond Therapeutics (BDTX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Black Diamond Therapeutics (BDTX) reported revenue of $70.0M for the first quarter 2025 (Q1 2025). Operating margin was 77.9%, net earnings $56.5M (80.8% of revenue).
Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.0M | — | — |
| Operating profit | $54.5M | — | — |
| Net earnings | $56.5M | — | — |
| Operating cash flow | $53.4M | — | — |
What changed
Revenue was $70.0M in Q1 2025.
Operating profit was $54.5M, a 77.9% margin. Net earnings were $56.5M. The effective tax rate was 0.4%.
Operating cash flow was $53.4M, 94% of net earnings. Non-cash charges added back $87K of depreciation and $1.7M of share-based compensation. Working capital and other items used $4.9M.
Questions
What was Black Diamond Therapeutics' revenue in the first quarter 2025?
Black Diamond Therapeutics (BDTX) reported revenue of $70.0M for the first quarter 2025 (Q1 2025).
Was Black Diamond Therapeutics profitable in the first quarter 2025?
Operating profit was $54.5M (77.9% of revenue) and net earnings $56.5M.